Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Modulation of Epigenetic Target in the Bone to Treat Breast Cancer Metastasis

Award Number: R01CA277838
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/03/2023
PERIOD OF PERFORMANCE END DATE: 06/30/2028

Group Awards By:

View Award Description

Modulation of Epigenetic Target in the Bone to Treat Breast Cancer Metastasis - PROJECT SUMMARY/ABSTRACT In the clinic, primary breast tumors are usually surgically removed soon after diagnosis, often leaving patients “tumor-free”. However, 20-40% of breast cancer survivors will eventually suffer metastasis to distant organs, sometimes years after surgeries. Bone metastasis is the most frequently occurring metastasis of breast cancer. Our long-term goals are to elucidate the biology underlying the survival and progression of bone metastases, which will inform the design of therapeutic strategies against these latent tumor cells, through a fruitful collaboration between labs at Rice University and Baylor College of Medicine. The overall goal of this proposal is to develop bone tumor-targeting epigenetic inhibitors and demonstrate their efficacy against bone micrometastases as well as further multi-organ metastases seeding from bone lesions. Our preliminary data establish that: (1) epigenetic inhibitors modified with bisphosphonates, have superb binding affinity for bone, and exhibit enhanced bone metastasis sites targeting in vivo; and (2) epigenetic inhibitors modified with bisphosphonates exhibited improved activities for inhibiting metastatic seeding from bone lesions to other organs; and (3) an intra-iliac artery (IIA) injection, developed in our lab, can be used to effectively model the bone metastatic niche, providing a powerful platform for evaluating the therapeutic efficacy against bone metastatic cancers and “metastasis-to-metastasis” seeding from bone lesions. Based on these results, the first research direction will focus on engineering current epigenetic inhibitors for breast cancer therapy with bone- homing moiety. Next, we will study their effects on the survival and progression of breast cancer bone metastases using both syngeneic and xenograft nude mouse models. Furthermore, we will dissect the molecular mechanisms underlying the benefits of bone tumor-targeting epigenetic inhibitors. An enhanced therapeutic profile for these bone-specific epigenetic inhibitors on breast cancer will inform the extension of these treatments to other bone cancers and diseases.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $652,042 )
2026	2026	WILLIAM MARSH RICE UNIVERSITY	6100 MAIN ST	HOUSTON	TX	77005	HARRIS	USA	Cancer Treatment Research	000	4	6/12/2026	NON-COMPETING CONTINUATION	$652,042
														Subtotal = $652,042

Issue Date FY: 2025 ( Subtotal = $652,042 )
2025	2025	WILLIAM MARSH RICE UNIVERSITY	6100 MAIN ST	HOUSTON	TX	77005	HARRIS	USA	Cancer Treatment Research	000	3	5/21/2025	NON-COMPETING CONTINUATION	$652,042
														Subtotal = $652,042

Issue Date FY: 2024 ( Subtotal = $619,441 )
2024	2024	WILLIAM MARSH RICE UNIVERSITY	6100 MAIN ST	HOUSTON	TX	77005	HARRIS	USA	Cancer Treatment Research	000	2	6/5/2024	NON-COMPETING CONTINUATION	$619,441
														Subtotal = $619,441

Issue Date FY: 2023 ( Subtotal = $666,169 )
2023	2023	WILLIAM MARSH RICE UNIVERSITY	6100 MAIN ST	HOUSTON	TX	77005	HARRIS	USA	Cancer Treatment Research	000	1	7/3/2023	NEW	$666,169
														Subtotal = $666,169

Grand Total All Awards = $2,589,694

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Modulation of Epigenetic Target in the Bone to Treat Breast Cancer Metastasis

Award Number: R01CA277838

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/03/2023

PERIOD OF PERFORMANCE END DATE: 06/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer